Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Brompton Energy Split Corp. Class A Shares (ESP.TO)

Brompton Energy Split Corp. Class A Shares (ESP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Brompton Funds Declares Split Share Fund Distributions Newsfile - Fri Feb 20, 10:34AM CST

Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - (TSX: DGS) (TSX: DGS.PR.A) (TSX: ESP) (TSX: GDV) (TSX: LBS) (TSX: LCS) (TSX: PWI) (TSX: SBC) - Brompton Funds announces distributions payable on...

DGS.TO : 8.36 (+2.20%)
ESP.TO : 7.37 (+1.24%)
LBS.TO : 12.30 (+1.32%)
SBC.TO : 14.98 (+0.47%)
PWI.TO : 13.07 (+0.46%)
LCS.TO : 9.09 (-0.98%)
GDV.TO : 13.23 (-0.15%)
Brompton Energy Split Corp. Announces Preferred Share Distribution Rate GlobeNewswire - Mon Jan 27, 2025

ESP.TO : 7.37 (+1.24%)
ESP-PR-A.TO : 10.25 (+0.20%)
Brompton Energy Split Corp. Establishes At-The-Market Equity Program GlobeNewswire - Thu Dec 19, 2024

ESP.TO : 7.37 (+1.24%)
ESP-PR-A.TO : 10.25 (+0.20%)
Brompton Energy Split Corp. Announces Extension of Term GlobeNewswire - Thu Nov 28, 2024

ESP.TO : 7.37 (+1.24%)
ESP-PR-A.TO : 10.25 (+0.20%)

Barchart Exclusives

Grail Stock Is Deeply Oversold on Cancer Test Failings. Is There Any Hope Left to Buy the Dip? Barchart - 35 minutes ago
Grail stock crashed on Friday after its NHS-Galleri clinical trial failed to meet primary endpoint. Here’s why investors are cautioned against treating GRAL shares as a bargain. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot